FLI1 and systemic sclerosis: Cyclophosphamide was demonstrated to exert a beneficial effect on Fli1 deficiency-dependent vasculopathy in a murine SSc model by improving the expression of endothelial Fli1, as well as angiogenesis and vasculogenesis effectors [115].